Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v4-FR Version v3-EN
Language French English
Date Updated 2024-10-01 2024-10-01
Drug Identification Number 02485559 02485559
Brand name RENVELA RENVELA
Common or Proper name Sevelamer carbonate Sevelamer carbonate
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients SEVELAMER CARBONATE SEVELAMER CARBONATE
Strength(s) 0.8G 0.8G
Dosage form(s) POWDER FOR SUSPENSION POWDER FOR SUSPENSION
Route of administration ORAL ORAL ORAL ORAL
Packaging size Sachet Sachet
ATC code V03AE V03AE
ATC description ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date
Actual start date 2024-07-22 2024-07-22
Estimated end date Unknown Unknown
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. Pending additional documentation. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. Pending additional documentation.
Health Canada comments